Screening and treatment of rifampicin-resistant pulmonary tuberculosis patients in Jingzhou, Hubei, 2016−2020

  Objective   To analyze the screening, detection and treatment of rifampicin-resistant pulmonary tuberculosis (TB) patients in Jingzhou, Hubei province, during 2016−2020, and explore the suitable rifampicin-resistant pulmonary TB control strategies and measures in Jingzhou.

  Methods   The drug resistant TB surveillance data in Jingzhou from 2016 to 2020 were collected through the “Tuberculosis Information Surveillance System”. The detection and treatment of rifampicin-resistant pulmonary TB patients in Jingzhou were evaluated and analyzed by screening rate, detection rate and treatment rate.

  Results   From 2016 to 2020, a total of 7 273 cases of etiological positive pulmonary TB cases were registered in Jingzhou, drug resistance screening were conducted for 3 885 cases, and 380 cases were rifampicin resistant. The screening rate of rifampicin resistance was 53.42% in the etiological positive pulmonary TB patients, which showed an increasing trend year by year (trend χ²=3 558.431, P<0.001). The detection rate of rifampicin resistance in pulmonary TB patients detected in drug resistance screening was 9.78%, and the detection rate of rifampicin resistance in retreatment patients (30.58%) was significantly higher than that in newly treated patients (5.85%) (χ²=360.348, P＜0.05), The detection rate of rifampicin resistance showed a decreasing trend year by year (trend χ²=263.254, P<0.001). The differences in the detection rate of rifampicin resistance were significant among counties (χ²=22.865, P<0.05), and the detection rates were higher in Jianli (13.15%) and Songzi (12.43%). From 2016 to 2020, the treatment rate of rifampicin resistant pulmonary TB patients diagnosed in Jingzhou was 78.95%, showing an upward trend (trend χ²=16.657, P=0.002).

  Conclusion   During 2016−2020, the screening rate and treatment rate of rifampicin resistant pulmonary TB patients in Jingzhou increased, and the detection rate of rifampicin resistance decreased. The prevention and control of drug-resistant TB has achieved certain results. During the next five years, we should further seek policy support, strengthen TB patient treatment management and infection control, and reduce the incidence of drug-resistant TB.